- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00459719
A Study to Compare the Efficacy and Safety of FK506MR vs Prograf® in Patients Undergoing Liver Transplantation
February 23, 2016 updated by: Astellas Pharma Inc
A Multicenter, Randomized, Open Label, Parallel Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Combination With Steroids in Patients Undergoing Liver Transplantation and a Pharmacokinetics Study.
The patients about to undergo liver transplantation will be randomized to one of the following two group:
Group FK506MR: FK506MR/steroid; Group Prograf® : Prograf® /steroid The treatment period is 3 months(12 weeks
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tianjin, China
-
-
Beijing
-
Beijing, Beijing, China
-
-
Guangdong
-
Guangzhou, Guangdong, China
-
-
Shanghai
-
Shanghai, Shanghai, China
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent with the date of the patient must be obtained.
- Patient between 18-70 years of age receiving the primary liver.
- Female patients must have a negative pregnancy test prior to the enrolment.
- Female patients of child bearing potential must agree to practice effective birth control during the study
Exclusion Criteria:
- Liver re-transplantation patients or received an organ transplantation other than a liver.
- Living-related liver transplantation patient.
- Patient has received an AB0 incompatible donor liver.
- Patient who needs antibody induction therapy.
- Patient with sever infection requiring treatment.
- Patient has any history of severe cardiovascular, respiratory disease; or history of malignancy, liver cancer not included.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
In combination with steroids
|
oral
Other Names:
|
Active Comparator: 2
In combination with steroids
|
oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Event rate of patients with acute rejections
Time Frame: 12 Weeks
|
12 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of and time to acute rejections
Time Frame: 12 Weeks
|
12 Weeks
|
Overall frequency of acute rejections
Time Frame: 12 Weeks
|
12 Weeks
|
Rate of patient and graft survival following transplantation.
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Prof. Leng Xisheng, Department of Hepatobiliary surgery
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2007
Primary Completion (Actual)
March 1, 2009
Study Completion (Actual)
March 1, 2009
Study Registration Dates
First Submitted
April 10, 2007
First Submitted That Met QC Criteria
April 11, 2007
First Posted (Estimate)
April 12, 2007
Study Record Updates
Last Update Posted (Estimate)
February 24, 2016
Last Update Submitted That Met QC Criteria
February 23, 2016
Last Verified
February 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MR4LTxCN01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplantation
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.Active, not recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine TransplantationBelgium, Czechia, France, Germany, Italy, Poland, United Kingdom
-
NovartisCompletedLiver Transplantation | Kidney TransplantationSwitzerland
-
University of Wisconsin, MadisonTerminatedLiver Transplantation | Kidney TransplantationUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingLiver Transplantation | Kidney TransplantationFrance
-
Astellas Pharma China, Inc.CompletedLiver Transplantation | Kidney TransplantationChina
Clinical Trials on Prograf
-
University Medicine GreifswaldCompletedHypercholesterolemia | Pharmacokinetics | Immunosuppression | Drug InteractionsGermany
-
National Taiwan University HospitalAstellas Pharma Taiwan, Inc.UnknownAdherence to Medication RegimeTaiwan
-
Veloxis PharmaceuticalsCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
Astellas Pharma IncCompleted
-
Veloxis PharmaceuticalsCompleted
-
HK inno.N CorporationNot yet recruitingHealthyKorea, Republic of
-
University of British ColumbiaSimon Fraser University; Astellas Pharma Canada, Inc.CompletedRenal Transplant | Renal DiseaseCanada
-
Astellas Pharma Europe Ltd.Active, not recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine TransplantationBelgium, Czechia, France, Germany, Italy, Poland, United Kingdom